Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of Pyridostigmine oral solution, which is used to treat myasthenia gravis [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Bromides of Pyridostigmine oral solution [1] - The drug was first launched in the United States in 1965, indicating a long history of use in the treatment of myasthenia gravis [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the oral solution, which is used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The oral solution of Bromides has been granted a drug registration certificate (Certificate No: 2025S04074) by the National Medical Products Administration [1] - The product was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - Shanghai Pharmaceuticals submitted the registration application for this product in April 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 2.3174 million in research and development for this product as of the date of the announcement [1] - There are currently no other companies in China that have this product listed for sale [1] Group 3: Market Potential - According to the IQVIA database, the procurement amount for Bromides tablets in hospitals in mainland China is RMB 60.29 million for the year 2024 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of bromhexine oral solution, indicating a significant advancement in its product portfolio [1] Group 1 - Shanghai Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd., has obtained a drug registration certificate for bromhexine oral solution [1] - The drug registration certificate number is 2025S04074, confirming the approval for production [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於溴吡斯的明口服溶液獲得批准生產的公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 10 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 证券代码：601607 证券简称：上 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for its oral solution of Pyridostigmine Bromide, which is approved for production [1] Group 1 - The oral solution of Pyridostigmine Bromide is used for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1965 [1] - Shanghai Shiyou submitted the registration application for this drug to the National Medical Products Administration in April 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 2.3174 million in research and development for this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

Group 1 - The core point of the article is that Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromides of the Ming oral solution, which is used to treat myasthenia gravis [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1965 [1] - As of the announcement date, the company has invested approximately 2.3174 million yuan in the research and development of this drug [1] Group 2 - There are currently no other companies in China that have this drug listed for sale [1]

关于溴吡斯的明口服溶液获得批准生产的公告 上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 编号：临 2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海上药中西 制药有限公司（以下简称"上药中西"）的溴吡斯的明口服溶液（以下简称"该 药品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注 册证书》（证书编号：2025S04074），该药品获得批准生产。 一、该药品基本情况 药品名称：溴吡斯的明口服溶液 剂型：口服溶液剂 规格：473ml：5.676g 注册分类：化学药品 3 类 药品批准文号：国药准字 H20256499 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 截至本公告日，中国境内该药品暂无其他企业上市。 IQVIA 数据库显示，2024 年中国大陆医院采购溴吡斯的明片剂金额为人民 币 6,029 万元。 1 三、对上市公司影响及 ...

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Bromides of the Ming oral solution, which is approved for production and is used to treat myasthenia gravis [1] Group 1 - The drug Bromides of the Ming oral solution was originally developed by BAUSCH and was first launched in the United States in 1965 [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601607 证券简称：上海医药 编号：临2026-001 上海医药集团股份有限公司 关于2019年A股股票期权激励计划预留股票期权第三个行权期2025年第四季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海医药集团股份有限公司（以下简称"上海医药"或"公司"）2019年A股股票期权激励计划（"本次股 权激励计划"）预留股票期权第三个行权期可行权的股票期权数量680,000份，行权期自2025年2月8日起 至2026年2月7日止。 ● 本次行权股票数量：2025年第四季度，公司预留股票期权第三个行权期激励对象未行权。 一、本次股权激励计划已履行的相关审批程序 1、2019年9月30日，公司召开第七届董事会第五次会议及第七届监事会第三次会议，审议通过了《关于 2019年股票期权激励计划（草案）及其摘要的议案》（以下简称"《股票期权激励计划（草案）》"）、 《关于2019年股票期权激励计划实施考核管理办法的议案》（以下简称 ...

证券代码：601607 证券简称：上海医药 编号：临2026-001 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划预留股票期权第三个行 权期 2025 年第四季度自主行权结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次股权激励计划已履行的相关审批程序 1、2019 年 9 月 30 日，公司召开第七届董事会第五次会议及第七届监事会 第三次会议，审议通过了《关于 2019 年股票期权激励计划（草案）及其摘要的 议案》（以下简称"《股票期权激励计划（草案）》"）、《关于 2019 年股票期权激 励计划实施考核管理办法的议案》（以下简称"《考核管理办法》"）、《关于提请 股东大会授权董事会办理 2019 年股票期权激励计划相关事宜的议案》。公司董事 中作为激励对象的关联董事左敏先生、李永忠先生及沈波先生均已回避表决。公 司独立董事基于独立客观判断，发表独立意见同意上述事项；公司监事会亦出具 核查意见。详见公司于 2019 年 10 月 1 日在指定信息披露媒体发布的相关 ...